Phase 1/2Terminated

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Lung Cancer (NSCLC)

Sponsor
Clovis Oncology, Inc. (Industry)
Enrollment
7 enrolled
Conditions
Non-small Cell Lung Cancer
Interventions
Rociletinib; Trametinib
Ages
adults, older adults
Registry
NCT02580708

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.

Primary outcomes

  • Incidence of treatment-emergent adverse events
  • Objective Response Rate (ORR)
  • Cmax of rociletinib and trametinib at steady state
  • Tmax of rociletinib and trametinib at steady state

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Registered

  5. Started